ORIC Pharmaceuticals

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies designed to counter resistance mechanisms in cancer. Its two clinical programs are enozertinib (formerly ORIC-114), a brain-penetrant, orally available irreversible inhibitor of EGFR and HER2 exon 20 insertion mutations that reported an 88% response rate in first-line EGFR exon 20 NSCLC in a Phase 1b update presented in October 2026, and rinzimetostat (formerly ORIC-944), an allosteric inhibitor of polycomb repressive complex 2 (PRC2) being developed in prostate cancer. Rinzimetostat is in Phase 3 testing in combination with androgen receptor inhibitors under clinical trial collaborations with Bayer (Nubeqa) and Johnson & Johnson (Erleada). The company was founded on research from the Sawyers, Lowe and Heyman laboratories and reported $388 million in cash and investments, a runway it has guided into the second half of 2028, past the rinzimetostat Phase 3 readout.